John Overdeck’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.65M | Sell |
28,775
-15,700
| -35% | -$860K | ﹤0.01% | 3171 |
|
|
2026
Q1 | $2.51M | Sell |
44,475
-25,291
| -36% | -$1.47M | ﹤0.01% | 2591 |
|
|
2025
Q4 | $4.15M | Sell |
69,766
-87,822
| -56% | -$4.78M | 0.01% | 1880 |
|
|
2025
Q3 | $8.53M | Buy |
157,588
+9,992
| +7% | +$571K | 0.01% | 1052 |
|
|
2025
Q2 | $8.11M | Sell |
147,596
-611,792
| -81% | -$36M | 0.01% | 940 |
|
|
2025
Q1 | $53.7M | Buy |
759,388
+526,580
| +226% | +$35.4M | 0.11% | 208 |
|
|
2024
Q4 | $15.3M | Sell |
232,808
-66,723
| -22% | -$4.47M | 0.03% | 579 |
|
|
2024
Q3 | $21.1M | Sell |
299,531
-40,919
| -12% | -$3.42M | 0.05% | 469 |
|
|
2024
Q2 | $28M | Sell |
340,450
-360,049
| -51% | -$30M | 0.06% | 353 |
|
|
2024
Q1 | $61.2M | Buy |
700,499
+286,534
| +69% | +$25.7M | 0.14% | 184 |
|
|
2023
Q4 | $39.9M | Sell |
413,965
-100,033
| -19% | -$8.85M | 0.09% | 265 |
|
|
2023
Q3 | $45.5M | Buy |
513,998
+84,810
| +20% | +$7.55M | 0.12% | 216 |
|
|
2023
Q2 | $37.2M | Sell |
429,188
-421,626
| -50% | -$39.7M | 0.09% | 264 |
|
|
2023
Q1 | $82.7M | Buy |
850,814
+84,442
| +11% | +$8.75M | 0.24% | 112 |
|
|
2022
Q4 | $79.3M | Buy |
766,372
+336,437
| +78% | +$31.6M | 0.25% | 98 |
|
|
2022
Q3 | $36.4M | Buy |
429,935
+327,581
| +320% | +$29.2M | 0.12% | 205 |
|
|
2022
Q2 | $8.48M | Sell |
102,354
-226,236
| -69% | -$18M | 0.03% | 568 |
|
|
2022
Q1 | $25.3M | Sell |
328,590
-32,761
| -9% | -$2.74M | 0.07% | 332 |
|
|
2021
Q4 | $31.9M | Buy |
361,351
+267,425
| +285% | +$22.1M | 0.07% | 333 |
|
|
2021
Q3 | $7.26M | Sell |
93,926
-6,600
| -7% | -$521K | 0.02% | 956 |
|
|
2021
Q2 | $8.39M | Buy |
+100,526
| New | +$7.97M | 0.02% | 906 |
|
|
2020
Q2 | – | Sell |
-63,636
| Closed | -$6.32M | – | 2961 |
|
|
2020
Q1 | $5.38M | Sell |
63,636
-137,252
| -68% | -$11.8M | 0.04% | 469 |
|
|
2019
Q4 | $17M | Sell |
200,888
-538,012
| -73% | -$40.6M | 0.05% | 420 |
|
|
2019
Q3 | $49.8M | Buy |
738,900
+255,449
| +53% | +$19.7M | 0.17% | 152 |
|
|
2019
Q2 | $41.4M | Buy |
483,451
+336,068
| +228% | +$28.7M | 0.14% | 179 |
|
|
2019
Q1 | $13.1M | Buy |
147,383
+126,018
| +590% | +$11.7M | 0.04% | 553 |
|
|
2018
Q4 | $1.82M | Buy |
21,365
+18,849
| +749% | +$1.79M | 0.01% | 1288 |
|
|
2018
Q3 | $244K | Buy |
+2,516
| New | +$251K | ﹤0.01% | 2889 |
|
|
2017
Q3 | – | Sell |
-49,039
| Closed | -$4.45M | – | 2749 |
|
|
2017
Q2 | $4.45M | Sell |
49,039
-26,357
| -35% | -$2.4M | 0.02% | 916 |
|
|
2017
Q1 | $6.62M | Buy |
+75,396
| New | +$6.71M | 0.02% | 792 |
|
|
2016
Q4 | – | Sell |
-96,330
| Closed | -$8.91M | – | 3103 |
|
|
2016
Q3 | $8.91M | Buy |
+96,330
| New | +$9.07M | 0.03% | 598 |
|
|
2016
Q1 | – | Sell |
-18,100
| Closed | -$1.47M | – | 2799 |
|
|
2015
Q4 | $1.9M | Sell |
18,100
-61,810
| -77% | -$6.45M | 0.01% | 1114 |
|
|
2015
Q3 | $8.42M | Buy |
79,910
+78,390
| +5,157% | +$10.5M | 0.04% | 397 |
|
|
2015
Q2 | $208K | Sell |
1,520
-2,240
| -60% | -$278K | ﹤0.01% | 2611 |
|
|
2015
Q1 | $469K | Sell |
3,760
-16,160
| -81% | -$1.71M | ﹤0.01% | 2015 |
|
|
2014
Q4 | $1.8M | Buy |
+19,920
| New | +$1.66M | 0.01% | 1069 |
|
|
2014
Q3 | – | Sell |
-6,720
| Closed | -$418K | – | 1759 |
|
|
2014
Q2 | $418K | Sell |
6,720
-76,047
| -92% | -$4.59M | ﹤0.01% | 1697 |
|
|
2014
Q1 | $5.65M | Buy |
+82,767
| New | +$6.1M | 0.03% | 589 |
|
|
2013
Q4 | – | Sell |
-333,203
| Closed | -$24.1M | – | 2179 |
|
|
2013
Q3 | $24.1M | Buy |
333,203
+214,961
| +182% | +$14.3M | 0.15% | 174 |
|
|
2013
Q2 | $6.6M | Buy |
+118,242
| New | +$7.37M | 0.05% | 446 |
|
Other funds holding BMRN
VPC
John Overdeck's BMRN Position: Q2 2026 in Review
John Overdeck reduced its BioMarin Pharmaceuticals (BMRN) stake by 35% in Q2 2026, selling an estimated $860K and leaving 28,775 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3171.
John Overdeck first reported a position in BMRN in Q2 2013 and has held it in 40 quarters since. The position peaked at $82.7M in Q1 2023. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.
- John Overdeck held 28,775 shares of BioMarin Pharmaceuticals worth $1.65M as of Q2 2026.
- John Overdeck sold 15,700 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $860K.
- BioMarin Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3171 holding.
- John Overdeck first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 40 quarters since.
- John Overdeck's BioMarin Pharmaceuticals position peaked at $82.7M in Q1 2023.
- 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.
Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.